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1. Introduction 
Nearly ten years ago Nephrologists began using asystem of classification for chronic kidney 
disease (CKD). This was established in 2002 by the Kidney Disease Outcome Quality 
Initiative (KDOQI) to estimate kidney function in a given patient regardless of the etiology 
of the primary insult to the kidneys. Physicians were able place their patients in stages from 
mild disease to end stage renal disease (ESRD).CKD is defined as glomerular filtration rate 
(GFR) below 60 ml/min per 1.73 m2 for 3 months or more. 
Each stage served as a “mile marker” on life’s road for the patient with CKD. The natural 
history of CKD usually is a steady decline in kidney function, as found in the relationship 
between the reciprocal of serum creatinine values and time. A percentage of patients do not 
follow this linear pattern, suggesting either worsening or improvement in their kidney 
function. Factors which may cause worsening of CKD in such individuals are often 
infections, dehydration, poor control of systemic blood pressure and exposure to 
nephrotoxins, in particular nonsteroidal anti-inflamatorydrugs and radiocontrast agents. 
Other individuals who do not follow the steady decline may actually show improvement in 
their GFR. The potential to improve the natural history of CKD is through tight blood 
pressure control and inhibition of rennin-angiotensin-aldosterone system.   
2. Stages of chronic kidney disease 
The early stages of kidney dysfunction are often clinically silent, especially when the 
condition is only slowly progressive and symptoms are nonspecific. Stages 1 & 2 show 
decreased kidney function without signs or symptoms of disease although the estimated 
GFR is less than 120 ml/min per 1.73 m2 but greater than 60 ml/min per 1.73 m2. The rate of 
progression is influenced by a wide range of factors which may or may not  have the 
potential of modification and varies among different individuals and with the underlying 
cause of nephropathy.When the patient enters Stage 3 he or she has lost approximately half 
their kidney function. It is less likely for the kidney disease to progress unless more than 
50% of the nephron function is lost. For example, individuals with a solitary kidney after 
unilateral nephrectomy for living kidney donation usually do not progress to 
CKD.Increased risk of natural progression with less than 50% of nephron loss can occur in 
persons of African ancestry with hypertensive nephrosclerosis. In 2008, the U.K National 
Institute of Health and Clinical Excellence (NICE) sub divided the stage 3 into 3A and 3B 
with estimated GFRs of 45 to 59 ml/min per 1.73 m2 and 44 to 30 ml/min per 1.73 m2 
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respectively. The NICE CKD guideline also suggested adding the suffix p to the stages in 
proteinuric patients.It has generally been assumed that the majority of patients with CKD 
stages 3B to 5 eventually progress to ESRD. A Canadian study showed the natural history of 
CKD stages 3 and 4 to be variable and reflecting the patient’s risk factor profile.Stage 4 may 
present with hyperkalemia or problems with salt and water retention. The kidneys are no 
longer able to adjust to abrupt changes in sodium, potassium and fluid intake (or loss). Prior 
to initiation of renal replacement therapy, the patient’s appetite may decrease, accompanied 
by weight loss and a decrease in the serum albumin. In CKD clinics, with patients seen at 
frequent intervals, the goal is to initiate dialysis before the patient becomes malnourished.  
 
Stage  Description GFR  (ml/min/1.73m2) 
1 Kidney damage with normal or ↑ GFR ≥ 90 
2 Kidney damage with mild ↓ GFR 60-89 
3 Moderate ↓ GFR 3A 45 – 59 
3B 30 - 44 
4 Severe ↓ GFR 15-29 
5 Kidney Failure < 15 (or dialysis) 
The suffix p to be added to the stage in patients with proteinuria > 0.5 g/24h 
Table 1. Stages of CKD. 
Two commonly used formulas to calculate creatinine clearance are the Cockcroft-Gault 
formula and MDRD formula. 
Cockcroft-Gault formula:      140 0.85
72
Age Mass Kgs if female
GFR
Serum Cr
     
Modification of diet in renal disease (MDRD) formula: 
   1.154 0.203186 . 1.212 0.742GFR SCr Age if black if female       
3. Risk factors 
It is estimated that by 2030,more than 2,000,000 Americans will need dialysis or 
transplantation. Who are these patients? What risk factors do they have?  
Low birth weight individuals with a decreased number of nephrons, the elderly 
population losing 1 ml/min/year after the age of 30 and Americans of African descent 
with hypertension, are several groups of individuals at risk.About one half of patients 
starting dialysis in America have diabetes mellitus, with hypertension the second largest 
group. Autoimmune disorders, infections, kidney stones, cystic kidneys and 
toxins/medications round out the list. Microalbuminuria may indicate systemic 
endothelial dysfunction and may be associated with a prothrombotic state. Insulin 
resistance is mediated in part by aldosterone; blocking the receptor attenuates 
cardiovascular and renal injury. 
The risk factors can be classified as those that increase the risk of development of kidney 
disease and those that increase the risk of adverse outcomes associated with CKD. The 
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factors which increase the risk for CKD are further classified into susceptibility and 
initiation factors; whereas factors which effect adverse outcomes are classified as 
progression factors and end stage factors. The association between variables and disease 
may be due to chance, a non-causal relation or may signify a true risk factor.  
3.1 Risk factors for development of CKD 
1. Susceptibility Factors 
A susceptibility factor is one that increases susceptibility to kidney damage following 
exposure to an initiation factor. An ideal study design to study these factors would be to 
identify a population of individuals who are free of kidney disease and are exposed to an 
initiation factor and follow them for a period of time. 
2. Initiation Factor 
An initiation factor is one that directly initiates kidney damage in an individual who is 
susceptible to kidney damage. An ideal study design for identification of initiation factors is 
a prospective cohort study. This would involve identification and follow up of a group of 
individuals free of kidney disease at baseline, with known susceptibility factors and with or 
without exposure to initiation factors, for the development of kidney disease. 
3.2 Risk factors effecting adverse outcome of CKD 
1. Progression Factors 
Progression factors worsen the kidney damage caused by initiation factors and lead to 
further decline in kidney function. Indicators of progression may include progression of 
microalbuminuria to overt proteinuria or reduced GFR, rate of decrease of GFR, or 
development of kidney failure necessitating dialysis or transplantation.  
2. End-Stage Factors 
End –stage factors are those that exacerbate the morbidity and mortality associated with 
kidney failure. Examples of indicators of mobidity include hospitalizations, poor quality of 
life measures, and cardiovascular disease complications.  
3.3 Risk factors for progression of chronic kidney disease 
1. Proteinuria 
Proteinuria is associated with faster rates of CKD progression. It contributes to nephron 
loss; filtered proteins are reabsorbed by the proximal tubular cells. Tubular cell contents 
may leak into the interstitium. This can cause macrophage infiltration and 
inflammatory mediators produced by them. The MDRD study showed proteinuria to be 
the strongest predictor of kidney disease progression in non diabetic patients. The REIN 
study done in non diabetic patients with proteinuria, showed the protein excretion rate 
to be the best single predictor of GFR decline to ESRD. This finding was independent of 
the initial insult.  
The US Collaborative Study in type 1 diabetic patients with >500mg proteinuria/day 
and serum creatinine values of 2.5mg% or less showed a 50% reduction in the risk of 
combined endpoints (death, dialysis, transplantation) in patients treated with an ACE 
inhibitor. 
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Risk Factor Definition Examples 
Susceptibility 
factors 
Increase susceptibility to 
kidney damage 
Older age, family history of chronic kidney 
disease, reduction in kidney mass, low 
birthweight, U.S. racial or ethnic minority 
status, low income or education 
Initiation 
factors 
Directly initiate kidney 
damage 
Diabetes, high blood pressure, 
autoimmune diseases, systemic infections, 
urinary tract infections, urinary stones, 




Cause worsening kidney 
damage and faster decline in 
kidney function after 
initiation of kidney damage 
Higher level of proteinuria, higher blood 




Increase morbidity and 
mortality in kidney failure 
Lower dialysis dose (Kt/V), temporary 
vascular access, anemia, low serum 
albumin level, late referral 
Table 2. Risk Factors for Chronic Kidney Disease and its Outcomes. 
The IDNT Study looked at type 2 diabetic patients treated with placebo, ibesartan or 
amlodipine. The ARB outperformed the placebo group and calcium channel patients in 
reaching doubling of the serum creatinine, ESRD, death by 20% and 23% respectively. 
2. Hypertension 
Blood pressure should be lowered to <120/80. 
Patients with blood pressure 120-129/80-84 have a 1.6 fold greater risk of developing 
ESRD and those with pressure >210/120 have a 4.2 fold risk of ESRD. 
The MRFIT study showed that hypertension was an independent risk factor for the 
development of ESRD. 
3. Smoking cessation- smoking is a risk factor in the progession to kidney failure 
Hallan, S & Orth, S. KI 2011.157 
4. Glycemic control 
Blood pressure control is more important with progression of CKD in the diabetic 
patient, whereas hyperglycemia is important with the initiation of diabetic 
nephropathy. 
5. Management of dyslipidemia 
LDL stimulates mesangial cell proliferation and the synthesis of proinflammatory 
molecules. 
No large study is available to show that control of lipids is effective in slowing the 
progression of CKD. The SHARP study showed that CKD patients receiving 
simvastatin and ezetimibe had approximately 15% fewer strokes and MIs. 
4. Mechanism of progression 
The characteristic structural change in CKD is scarring associated with glomerulosclerosis, 
tubulointerstitial fibrosis, and vascular sclerosis. After this initial insult the kidney goes 
down on one of the two paths, healing and functional recovery or scarring with loss of 
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kidney function progressing to CKD. It is less known what  leads the kidney to which 
pathway.  
Healing primarily occurs in Acute Kidney Injury (AKI) and acute interstitial nephritis, when 
treatment is instituted early in its course. Healing is also a hallmark of acute post infectious 
glomerulonephritis. Renal function typically recovers within few weeks of acute nephritic 
process.Chronic kidney damage on the other hand is usually induced by diabetes, 
hypertension, chronic glomerulonephritits, or chronic exposure to infections or 
nephrotoxins, progress to scarring with loss of function and CKD. (Fig. 1) 
 
Fig. 1. Progression of initial kidney injury. 
Renal cell injury results in loss of glomerular capillaries and cellular elements are replaced 
by extracellular matrix and fibrous tissue. Acute severe glomerulonephritis damages the 
capillaries and endothelium whereas sub-acute and chronic glomerulonephritis affect the 
mesangium or the podocytes. Progressive renal scarring is associated with progressive 
tubular cell loss and atrophy. 
4.1 Role of intrinsic renal cells in kidney damage 
Endothelium: Damage to the protective anticoagulant and anti-inflamatory endothelial 
capillary lining in acute glomerulonephritis, transforms it into a pro-inflammatory surface 
leading to accumulation of inflammatory cells and platelets within golmerular capillaries as 
well as the stimulation of mesangial proliferation. Glomerular endothelial damage can also 
be due to a metabolic insult as in diabetes or a physical hemodynamic stress as in 
hypertension.  
Mesangium: Mesangial cells respond to injury either with death, transformation, 
proliferation and migration,or synthesis and deposition of extracellular matrix (ECM). 
Scarring is usually characterized by uncontrolled mesangial proliferation and excessive 
deposition of mesangial matrix. This process is driven by a number of growth factors like 
transforming growth factor β1 (TGFβ1), platelet derived growth factor (PDGF), and 
fibroblast growth factor (FGF).  
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Podocytes: After an injury to the podocytes, the glomerular basement membrane is exposed 
to the parietal epithelial cells leading to the formation of capsular adhesions and segmental 
glomerulosclerosis. This may lead to misdirected filtration with accumulation of amorphous 
material in the glomerular space. Misdirected filtration causes disruption of the glomerular-
tubular junction resulting in atubularglomeruli. It may also contribute to tubular atrophy 
and interstitial fibrosis. Thus podocytes help in conserving the structural integrity of the 
glomerulus by forming a protective membrane over the basement membrane. 
Tubular cells: As mentioned earlier, after the initial insult the tubular cells may undergo 
healing and recover renal function, but repeated insults stimulate epithelial mesenchymal 
transformation of tubular cells to myofibroblastic phenotype with excessive deposition of 
ECM. Thus tubular injury can lead to renal fibrogenesis.  
Vascular cells: Vascular sclerosis is an intergral feature of renal scarring and is associated 
with progressive kidney failure in glomerulonephritis. Hyalinosis of afferent arterioles, in 
diabetes, and damage to the post-glomerular arteriole and peritubular capillaries cause 
interstitial ischemia and fibrosis. 
 
Fig. 2. Role of Intrinsic Cells in Kidney Damage. 
4.2 Role of extrinsic cells in kidney damage 
Infiltration of inflammatory cells into the glomeruli and the renal interstitium is the 
hallmark of glomerulosclerosis and tubuloiterstitial fibrosis. 
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Platelets and coagulation: Platelets and their release products within the damaged glomeruli 
stimulate a coagulation cascade which activate the mesangial cells to induce sclerosis. 
Thrombin stimulates glomerular TGF-β1 leading to production of mesangial ECM and 
inhibition of metalloproteinases.  
Lymphocytes, Monocytes-Macrophages, Dendritic cells play important role in the formation 
of glomerulosclerosis by causing inflammation. 
 
Fig. 3. Deposition on of ECM within and around the glomerulus. 
 
Fig. 4. Glomerular hypercellularity due to proliferation of intrinsic glomerular cells and 
intracapillary leukocytes. 
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Fig. 5. Capillary tufts almost replaced by the fibous tissue forming glomerular scarring. 
 
Fig. 6. Immunofluorescent stain shows deposition of coarsely granular deposits of 
complement C3. 
4.3 Role of angiotensin II, hypertension and hyperfiltration 
With progression of kidney disease the afferent arteriole tone decreases to a much larger 
extent than the efferent tone. As a result intra-glomerular pressure rises leading to 
hyperfiltration. Angiotensin II aides in hyperfiltration through its vasoconstrictor effect 
predominantly on the efferent arteriole. Apart from its hemodynamic effects, Angiotensin II 
acts directly on the glomerular membrane. It acts on the angiotensin II receptors on the 
surface of the podocytes, altering their permselective property, by contracting the foot 
processes. This allows  proteins to escape in the urinary space.  
Angiotensin II also induces proliferation ofglomerular cells and fibroblasts. It acts on AT1 
receptors on tubular cells causing hypertrophy, which results in increased synthesis of 
collagen type IV. It increases macrophage activation and phagocytosis responsible for the 
inflammatory component associated with CKD. 
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4.4 Role of proteinuria 
Proteinuria is not only a marker of kidney damage, but also contributes to nephron damage. 
Filtered proteins are reabsorbed from the proximal tubule. Damaged tubular basement 
membrane causes leakage of tubular content into the interstitium, thereby causing 
macrophage infiltration. Macrophages produce inflammatory mediators thus mounting an 
immense inflammatory reaction inside the renal interstitium. 
 
Fig. 7. Focal segmental and global Glomerulosclerosis and nephron loss is a vicious circle 
ultimately leading to proteinuria. 
5. Pathology of CKD 
Fibrosis in the kidneys initiated by a variety of insults may not be a uniform process. 
Progressive disease in diabetic patients may be related to endothelial nitric oxide deficiency 
with resultant endothelial dysfunction.The eventual pathology of the above mentioned 
series of events lead to two major histologic characteristic of CKD, focal segmental 
glomerulosclerosis and tubulointerstitial fibrosis. An initial insult to the kidneys will cause 
nephron loss.The remaining nephrons work harder to compensate for the lost nephrons 
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(compensatory hypertrophy). This leads to hemodynamic changes including glomerular 
hypertension and hyperfiltration. There is reduced afferent arteriolar resistance and 
intraglomerular pressure rises with increased filtration by the remaining nephrons. The 
intrinsic and extrinsic cells contribute to sclerosis as mentioned above contributing to the 
focal and segmental glomerulosclerosis. 
Tubulointerstitial injury results from ischemia of tubule segments downstream from 
sclerotic glomeruli. Acute and chronic inflammation in the adjacent interstitium, and 
damage of pericapillary blood supply also contribute to tubular injury. The above events 
along with proteinuria eventually lead to tubulointerstitial fibrosis.  
Angiotensin II increases vascular tone (predominantly post-glomerular) and affects 
intraglomerular pressure. The increased pressure alters the structure of the pores in the 
glomerular basement membrane (GBM) and increases proteinuria. 
5.1 Clinical manifestation and management 
What is the best way to manage these individuals? In the outpatient setting, achecklist for 
each patient ensures that each individual’s needs are met. A list of “ten commandments” for 
the CKD patient is: 
1. Estimate the GFR and stage the patient’s CKD. 
2. Round up the usual suspects. Diabetes and hypertension account for almost ¾ of the 
patient population. Urinalysis, serologies, sonography and biopsy (if necessary) to 
make the diagnosis. 
3. Fix what you can. Discontinue NSAIDs, correct volume depletion and treat BPH (men) 
and bladder dysfunction (women). 
4. Treat hypertension. Goal of therapy is <130/80. 
Use ACE, ARB, both, renin blockers, calcium channel blockers, aldosterone antagonists, 
loop diuretics as needed. 
5. Measure (spot urine protein /creatinine) and treat proteinuria. The goal is<300mg/day. 
Maximize the dose of an ACE inhibitor, then add an ARB at ½ full dose and increase to 
reach goal. Loop diuretics are essential to manage edema fluid and offset the 
development of hyperkalemia. Renin blockers and aldosterone antagonists are added 
with monitoring of the patient’s potassium and creatinine. If the potassium rises to 
greater than 5.5 meq/l or if the serum creatinine increases more than 30% above 
baseline, dosages will need to be decreased. 
6. Treat anemia of CKD with an ESA if there is no blood loss and iron stores are adequate. 
Check thyroid function, B-12, folic acid levels. The target Hgb is >10g/dl. Parenteral 
iron may be needed  to keep the TSAT > 25%. 
7. Give base supplements to correct metabolic acidosis. Untreated acidosis causes 
osteopenia and muscle catabolism, along with the release of calcium and phosphorous 
from bone. Sodium bicarbonate is replaced at 0.5-1.0 meq/kg/day. 
Treat hyperurricemia with allopurinol if the eGFR is >30 ml/min. 
8. Phosphate binders, precursor vitamin D and active D (when necessary). We are using 
both calcium and non-calcium containing binders in our clinic. We try to keep serum 
calcium levels less than or equal to 9.5 mg%. Vitamin D2 and 3 are used in patients with 
25(OH)D levels less than 30 ng/ml. Active vitamin D is used to control elevated iPTH 
levels and the effects of secondary HPT.  
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9. Have a nutritionist help patients maintain caloric intake. Protein restriction is difficult 
and may lead to malnutrition in patients with already poor appetites. We encourage 
protein supplementation in our CKD patients. The phosphorus level will increase, 
however, we try to maintain the patient’s albumin predialysis or pretransplantation. 
Patients are started on a 2 gram potassium diet and educated about avoidance of foods 
high in potassium. Loop diuretics + base supplements aid in the management of 
hyperkalemia. Resin exchange binders are reserved for values greater than 6 as they 
cause diarrhea, bicarbonate loss and may worsen acidemia and further increase the 
serum potassium value. 
10. Education and preparation for hemodialysis or peritoneal dialysis. See if acandidate is 
available for transplantation. We encourage patients to have a fistula constructed after 
they have attended the education class and decide to do in center or home 
hemodialysis. These are patients generally in late stage 3 CKD. 
Diabetic patients should maintain euglycemia, insulin requirements may decrease as CKD 
progresses. Metformin should be avoided and glipizide isthe preferred oral agentbecause it 
is not downgraded to a metabolite excreted by the kidneys. 
6. Summary 
CKD will remain a health concern into the future. CKD clinics managing patients in a 
coordinated fashion with nutritionists and surgeons will improve lives. Better blood 
pressure control with diminution of proteinuria will slow the progress of established 
disease. Attention to acidemia and hyperruricemia will also be beneficial. New insights into 
the pathogenesis and treatment of diabetes may help manage the number one cause of 
kidney failure in America. 
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